Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID‐19 trial of nirmatrelvir

RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - Wiley Online Library
Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …
被引用次数：99 相关文章
[PDF] scienceopen.com

[PDF][PDF] Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir

RSP Singh, SS Toussi, F Hackman, PL Chan, R Rao… - scienceopen.com
METHODS Objectives, participants, and oversight This 5-part study (NCT04756531)
assessed nirmatrelvir safety, tolerability, and pharmacokinetics following single-ascending …

Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir.

RSP Singh, SS Toussi, F Hackman, PL Chan, R Rao… - 2022 - cabidigitallibrary.org
Abstract Coronavirus disease 2019 (COVID-19) is a continued leading cause of
hospitalization and death. Safe, efficacious COVID-19 antivirals are needed urgently …

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir

RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Coronavirus disease 2019 (COVID-19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID-19 antivirals are needed urgently. Nirmatrelvir (PF …
[PDF] archive.org

[PDF][PDF] Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir

RSP Singh, SS Toussi, F Hackman, R Rao, R Allen… - scholar.archive.org
Background: COVID-19 is a continued leading cause of hospitalization and death. Safe and
efficacious COVID-19 antivirals are needed urgently. Nirmatrelvir (PF-07321332), the first …
[HTML] nih.gov

[HTML][HTML] Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID‐19) is a continued leading cause of
hospitalization and death. Safe, efficacious COVID‐19 antivirals are needed urgently …

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - europepmc.org
Abstract Coronavirus disease 2019 (COVID‐19) is a continued leading cause of
hospitalization and death. Safe, efficacious COVID‐19 antivirals are needed urgently …

Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir

RSP Singh, SS Toussi, F Hackman, PL Chan, R Rao… - medRxiv, 2022 - medrxiv.org
Background COVID-19 is a continued leading cause of hospitalization and death. Safe and
efficacious COVID-19 antivirals are needed urgently. Nirmatrelvir (PF-07321332), the first …

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - europepmc.org
Abstract Coronavirus disease 2019 (COVID‐19) is a continued leading cause of
hospitalization and death. Safe, efficacious COVID‐19 antivirals are needed urgently …